177Lu-DOTATATE (PRRT)
Checked 2026-09-09
SSTR-positive gastroenteropancreatic NET after somatostatin analogue
One cycle
every 56 days × 4 · about 32 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Lutetium-177 dotatate Radioligand therapy (beta) | 7.4 GBq | IV | D1 | with amino-acid infusion for renal protection |
Octreotide LAR Peptide hormone analogue (SSTR2 agonist) | 30 mg | SC | D1 | given after each dose; continue during and after treatment |
Cycles
4
56-day cycle
Emetogenicity
Low (10-30%)
G-CSF
Not routine
Used in
Trials
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
CAPTEM
Advanced pancreatic neuroendocrine tumour
every 28 days
Everolimus
Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy
every 28 days
Cisplatin + etoposide (EP)
Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma
every 21 days × 4
Sunitinib 4/2
Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET
every 42 days